Sectoral Asset Management Inc grew its position in Loxo Oncology, Inc. (NASDAQ:LOXO) by 10.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 245,226 shares of the biopharmaceutical company’s stock after acquiring an additional 23,431 shares during the quarter. Loxo Oncology comprises 2.9% of Sectoral Asset Management Inc’s holdings, making the stock its 8th largest position. Sectoral Asset Management Inc owned 0.82% of Loxo Oncology worth $22,590,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in LOXO. Legal & General Group Plc increased its holdings in shares of Loxo Oncology by 8.4% in the first quarter. Legal & General Group Plc now owns 3,682 shares of the biopharmaceutical company’s stock valued at $154,000 after purchasing an additional 284 shares during the last quarter. Ameritas Investment Partners Inc. increased its stake in Loxo Oncology by 31.3% during the second quarter. Ameritas Investment Partners Inc. now owns 1,758 shares of the biopharmaceutical company’s stock worth $141,000 after acquiring an additional 419 shares during the last quarter. Wells Fargo & Company MN increased its stake in Loxo Oncology by 3.8% during the second quarter. Wells Fargo & Company MN now owns 16,095 shares of the biopharmaceutical company’s stock worth $1,291,000 after acquiring an additional 592 shares during the last quarter. New York State Common Retirement Fund increased its stake in Loxo Oncology by 2.9% during the third quarter. New York State Common Retirement Fund now owns 25,097 shares of the biopharmaceutical company’s stock worth $2,312,000 after acquiring an additional 700 shares during the last quarter. Finally, California State Teachers Retirement System increased its stake in Loxo Oncology by 3.1% during the third quarter. California State Teachers Retirement System now owns 36,594 shares of the biopharmaceutical company’s stock worth $3,371,000 after acquiring an additional 1,094 shares during the last quarter.

Several research firms have issued reports on LOXO. BidaskClub raised Loxo Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. Zacks Investment Research cut Loxo Oncology from a “buy” rating to a “hold” rating in a research note on Saturday, August 12th. Stifel Nicolaus reissued a “buy” rating and set a $94.00 target price (up previously from $71.00) on shares of Loxo Oncology in a research note on Thursday, August 10th. William Blair began coverage on Loxo Oncology in a research note on Tuesday, November 28th. They set an “outperform” rating for the company. Finally, Citigroup cut their target price on Loxo Oncology from $112.00 to $108.00 and set a “buy” rating for the company in a research note on Thursday, November 16th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Loxo Oncology currently has an average rating of “Buy” and a consensus target price of $90.57.

In related news, CEO Joshua H. Bilenker sold 15,000 shares of Loxo Oncology stock in a transaction on Tuesday, November 28th. The stock was sold at an average price of $74.45, for a total value of $1,116,750.00. Following the completion of the transaction, the chief executive officer now directly owns 182,707 shares in the company, valued at $13,602,536.15. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Avi Z. Naider sold 5,000 shares of Loxo Oncology stock in a transaction on Wednesday, September 13th. The shares were sold at an average price of $90.00, for a total value of $450,000.00. Following the completion of the transaction, the director now owns 154,118 shares of the company’s stock, valued at $13,870,620. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,123,596 shares of company stock valued at $84,872,356. Company insiders own 44.40% of the company’s stock.

Loxo Oncology, Inc. (NASDAQ:LOXO) opened at $79.63 on Friday. Loxo Oncology, Inc. has a 52-week low of $25.25 and a 52-week high of $95.92.

TRADEMARK VIOLATION WARNING: This piece was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.watchlistnews.com/loxo-oncology-inc-loxo-shares-bought-by-sectoral-asset-management-inc/1750981.html.

Loxo Oncology Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Want to see what other hedge funds are holding LOXO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Loxo Oncology, Inc. (NASDAQ:LOXO).

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.